First Pill for Postpartum Depression Is Approved by FDA
The pill, to be taken daily for at least two weeks, significantly reduced postpartum depression among new mothers in a...
Biogen
Biogen Buying Rare-Disease Drugmaker in $7.3 Billion Deal
The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. Source link
FDA Approves Leqembi, Extending Alzheimer’s Treatment to More Patients
Medicare enrollees can get the anti-amyloid treatment as a result of the agency’s full approval. Source link
New Alzheimer’s Drug Leqembi Will Be Out of Reach for Most Patients
HealthMedicare won’t pay for medicine under rule issued to restrict use of earlier drug whose approval generated controversy Source link
Amylyx Prices Newly Approved ALS Drug at $12,500 a Month
The drug, called Relyvrio, was approved by the Food and Drug Administration late Thursday after some staff had raised questions...
Alzheimer’s Drug Slows Disease Progression in Trial
The pharmaceutical companies said their drug lecanemab reduced cognitive and functional decline by 27%, compared with a placebo, over 18...
Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments
Biogen Inc. agreed to pay $900 million to settle allegations that it paid kickbacks to doctors to induce them to...
Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics
Biogen Inc. is selling its share in biosimilar joint venture Samsung Bioepis for at least $2.25 billion to partner Samsung...
Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients
Medicare officials said they would cover Biogen Inc.’s BIIB 2.64% controversial Alzheimer’s disease drug Aduhelm on the condition that patients...
Cleveland Clinic, Mount Sinai and Providence Won’t Give Biogen’s New Alzheimer’s Drug
Three large hospitals are declining to administer Biogen Inc.’s BIIB -6.79% new Alzheimer’s treatment, Aduhelm, the latest rupture to emerge...
FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns
The U.S. Food and Drug Administration approved the first new Alzheimer’s drug in decades over the objection of agency statisticians...
